
Opinion|Videos|July 17, 2024
Clinical Approaches in High-Risk Patients with CLL/SLL
Author(s)Mazyar Shadman, MD, MPH
Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following questions:
- How would you describe your current clinical approach for high-risk patients with CLL/SLL, including those with or without del(17p) and/or TP53 mutations?
- What are the goals of therapy for patients in this setting?
- What are some challenges and unmet needs for patients with CLL/SLL?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















